Navigation Links
Effectene Transfection Reagent

For transfection of a wide variety of cells, particularly effective for primary cells

Features and benefits
  • Fast and easy transfection
  • No transfection-complex removal needed for most cell lines
  • Transfection in the presence of serum
  • Ideal for primary cells or sensitive cell lines
  • High transfection efficiencies and minimal cytotoxicity
  • Low DNA requirement
Principle

Effectene Transfection Reagent is an innovative non-liposomal lipid formulation that is used in conjunction with a special DNA-condensing enhancer and optimized buffer to achieve high transfection efficiencies. The enhancer first condenses the DNA molecules and Effectene Reagent subsequently coats them with cationic lipids (see figure "Model of Effectene Principle"), providing a particularly efficient way of transferring DNA into eukaryotic cells. Effectene Reagent offers significant advantages over many liposome reagents and other transfection methods (1, 2).

Model of Effectene Principle

High Transfection Efficiencies Using Effectene Reagent
Comparison of transfection efficiencies using Effectene Reagent and two commonly used lipid-based reagents. Murine teratocarcinoma F9 cells (5 x 105) were transfected in 6-well plates with a luciferase-reporter plasmid using optimized conditions based on the manufacturer's instructions for each reagent. Transfection efficiencies were determined by measuring luciferase activity 48 h post-transfection, and are given as relative light units (RLU). (Data kindly provided by I. Clavereau, D. Petitprez, and I. Van Seuningen, Unit INSERM 377, Place de Verdun, Lille Cedex, France.)


Transfection of Oligonucleotides Using Effectene Reagent



C6 glioblastoma cells (1 x 104) were transfected with either naked FITC-labeled CD44 antisense oligodeoxynucleotide (ODN) or with EffecteneODN complexes. Intracellular accumulation and distribution of the transfected ODNs was analyzed 16 h post-transfection by immunofluoresence. A Naked ODNs (2 g). B ODNs (0.04 g) complexed with Effectene Reagent. Transfected ODNs are green in the photos. (Data kindly provided by G. Beutel and M. Schott, Institute of Neuropathology, Hanover Medical School, Hanover, Germany.)

Procedure

The Effectene procedure has two steps. DNA is first mixed with Enhancer and a buffer that provides optimal salt conditions for efficient DNA condensation. This step requires just 25 minutes. Effectene Reagent is then added and the mixture is incubated for 510 minutes to allow EffecteneDNA complexes to form. The complexes are mixed with growth medium (which can contain serum and antibiotics), and added directly to the cells. The cells are then incubated until harvested and analyzed for gene expression.

Applications

Effectene Reagent is suitable for transient and stable transfection of a broad rang e of cell types (see figures "High Transfection Efficiencies Using Effectene Reagent" and "Transfection of Oligonucleotides Using Effectene Reagent"). Because transfection can be performed in the presence of serum and requires low amounts of DNA (see figure "Serum and DNA Quantity vs. Transfection Efficiency"), cytotoxicity is minimal. This makes Effectene Reagent particularly effective for primary cells (see figure "Effectene Reagent with Primary Cells"). A searchable list of cell lines and primary cells successfully transfected using Effectene Reagent, as well as customer-developed transfection protocols, is available at the Transfection Tools web site www.qiagen.com/transfectiontools/.

Serum and DNA Quantity vs. Transfection Efficiency



Influence of serum and DNA quantity on transfection using Effectene Reagent. 2 x 104 COS-7 cells were seeded per well in 96-well plates one day before transfection. Cells were transfected using 0.011.0 g of a beta-galactosidasereporter plasmid and 0.088.0 l Enhancer (DNA: Enhancer ratio of 1:8) and 2 l Effectene Reagent, in either the presence or absence of serum. Each bar represents the average efficiency from four replicates 48 h post-transfection.

Effectene Reagent with Primary Cells



Expression of green fluorescent protein (GFP) in primary rabbit aortic smooth muscle cell s transfected using Effectene Reagent. 1 x 105 cells were seeded one day prior to transfection, and transfections were performed in 6-well plates using 0.4 g of a GFP-reporter plasmid and 10 l Effectene Reagent per well. Cells were viewed 24 h post-transfection by fluorescence microscopy. Approximately 40% of the cells were transfected, as determined by FACS analysis. (Data kindly provided by K. Veit, 2nd Medical Clinic, Dept. Clinical Pharmacology, Mainz, Germany.)

High-throughput transfection

The application of recombinant DNA technology to fields such as drug discovery and development has led to an increased need for high-throughput transfection. Transfection using Effectene Reagent requires low amounts of DNA and minimal handling, and in addition, removal of transfection complexes is not required, making this reagent highly suitable for high-throughput screening. Effectene Reagent provides outstanding transfection efficiencies, excellent reproducibility, and minimal cytotoxicity in high-throughput transfection, and is available in bulk quantities.

Cited References

1. Ausubel, F.M., et al. eds. (1991) Current Protocols in Molecular Biology, Wiley Interscience, New York.
2. Sambrook, J., Fritsch, E.F., and Maniatis, T., eds. (1989) Molecular cloning a laboratory manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.



'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
2. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
3. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
4. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
5. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
6. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
7. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
8. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
9. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
10. Efficient Transfection of Neurospora Crassa
11. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):